Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN012
MIFTS: 42

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenocarcinoma in Situ

About this section

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 43 15 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4943
MeSH 43 D065311
NCIt 49 C4123
SNOMED-CT 67 51642000
UMLS 71 C0334276
Sources

Summaries for Adenocarcinoma in Situ

About this section
Disease Ontology : 12 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to pulmonary adenocarcinoma in situ and early invasive cervical adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Pathways in cancer and Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and testes, and related phenotypes are Reduced mammosphere formation and cellular

Sources

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 pulmonary adenocarcinoma in situ 33.4 KRAS EGFR ALK
2 early invasive cervical adenocarcinoma 32.3 INSM1 CDKN2A
3 neuroendocrine carcinoma 30.7 KRT7 KRT20 CEACAM5
4 papillary adenocarcinoma 30.6 KRT7 KRAS CEACAM5 CDX2
5 urachal adenocarcinoma 30.4 KRAS CEACAM5
6 anal gland adenocarcinoma 30.4 KRT7 CDX2
7 adenoma 30.3 KRT7 KRT20 KRAS CDX2 CDKN2A
8 in situ carcinoma 30.3 GGN EGFR CDKN2A
9 appendix adenocarcinoma 30.3 KRT7 KRT20 KRAS CEACAM5 CDX2
10 cervical adenocarcinoma 30.3 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
11 cystadenoma 30.2 KRT7 KRT20 CEACAM5
12 mature teratoma 30.2 KRT7 KRAS CEACAM5
13 glandular cystitis 30.2 KRT7 KRT20 CDX2
14 duodenum adenocarcinoma 30.0 KRT7 KRAS CEACAM5 CDX2
15 villous adenoma 30.0 KRT20 KRAS CEACAM5 CDX2
16 endocervical adenocarcinoma 29.9 U2AF1 PAX8 PAX2 KRT7 KRT20 CEACAM5
17 mammary paget's disease 29.9 KRT7 KRT20 EGFR
18 pseudomyxoma peritonei 29.8 KRT7 KRT20 KRAS CEACAM5 CDX2
19 endometrial adenocarcinoma 29.8 KRT7 KRAS EGFR CDKN2A
20 benign teratoma 29.8 PAX8 KRT7 KRT20 CEACAM5 CDX2
21 adenosquamous carcinoma 29.8 KRT7 KRAS EGFR CEACAM5
22 cystic teratoma 29.6 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
23 teratoma 29.6 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
24 papilloma 29.3 KRT7 KRT20 KRAS EGFR CDKN2A
25 adenocarcinoma 29.3 U2AF1 KRT7 KRT20 KRAS EGFR CEACAM5
26 barrett esophagus 29.3 MCM2 KRT7 KRT20 EGFR CDX2 CDKN2A
27 bronchiolo-alveolar adenocarcinoma 29.3 U2AF1 KRT7 KRT20 KRAS EGFR CEACAM5
28 intrahepatic cholangiocarcinoma 29.3 KRT7 KRT20 KRAS EGFR CDX2
29 ovarian mucinous neoplasm 29.2 U2AF1 PAX8 KRT7 KRT20 KRAS CEACAM5
30 squamous cell carcinoma 29.1 U2AF1 KRT7 EGFR CEACAM5 CDKN2A
31 colorectal adenocarcinoma 29.1 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
32 transitional cell carcinoma 29.1 U2AF1 KRT7 KRT20 EGFR CDKN2A
33 peritoneum cancer 29.0 WT1 PAX8 KRT7 EGFR CEACAM5 CDKN2A
34 colon adenocarcinoma 29.0 KRT20 KRAS EGFR CEACAM5
35 endometrial cancer 28.8 WT1 PAX8 KRT7 KRT20 KRAS EGFR
36 large cell neuroendocrine carcinoma 28.8 KRT7 KRT20 EGFR ALK
37 cholangiocarcinoma 28.6 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
38 mucinous adenocarcinoma 28.5 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
39 lung cancer susceptibility 3 28.2 U2AF1 TOP2A KRT7 KRT20 KRAS EGFR
40 gastric adenocarcinoma 27.8 TOP2A MCM7 KRT7 KRT20 KRAS EGFR
41 cervical basaloid squamous cell carcinoma 10.6 KRT7 CDKN2A
42 trachea carcinoma in situ 10.6 KRAS CDKN2A
43 leukoplakia of penis 10.6 KRT7 CEACAM5
44 signet ring basal cell carcinoma 10.6 KRAS CEACAM5
45 parotid gland adenoid cystic carcinoma 10.6 CEACAM5 CDKN2A
46 inverted transitional papilloma 10.6 KRT7 CDKN2A
47 ovary neuroendocrine neoplasm 10.6 KRT7 CDX2
48 cervical adenoid cystic carcinoma 10.5 KRT7 CDKN2A
49 apocrine adenoma 10.5 KRT7 KRAS
50 rete testis neoplasm 10.5 PAX8 KRT7

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ
Sources

Symptoms & Phenotypes for Adenocarcinoma in Situ

About this section

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CLDN1 EGFR KRAS KRT7 MCM2 MCM7

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 CDKN2A CDX2 EGFR GGN INSM1 KRAS
2 growth/size/body region MP:0005378 10.1 ALK ASPH CDKN2A CDX2 CLDN1 EGFR
3 homeostasis/metabolism MP:0005376 10.1 ALK ASPH CDKN2A CDX2 CLDN1 CLDN10
4 endocrine/exocrine gland MP:0005379 10.07 ALK CDKN2A CDX2 EGFR INSM1 KRAS
5 mortality/aging MP:0010768 10.03 ALK ASPH CDKN2A CDX2 CLDN1 EGFR
6 neoplasm MP:0002006 9.56 ALK ASPH CDKN2A CDX2 EGFR KRAS
7 pigmentation MP:0001186 9.1 ALK CDKN2A EGFR KRAS MCM2 PAX2
Sources

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2 Immunologic Factors Phase 3
3
Metformin Approved Phase 2 657-24-9 14219 4091
4
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
5
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
6
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 10204 6013
7
Ipilimumab Approved Phase 2 477202-00-9
8
nivolumab Approved Phase 2 946414-94-4
9 Molgramostim Investigational Phase 1, Phase 2 99283-10-0
10 Hypoglycemic Agents Phase 2
11 Hormones Phase 1, Phase 2
12 Alkylating Agents Phase 1, Phase 2
13 Immunosuppressive Agents Phase 1, Phase 2
14 Androgens Phase 1, Phase 2
15 Antirheumatic Agents Phase 1, Phase 2
16 Immunoglobulins Phase 2
17 Antibodies Phase 2
18 Antibodies, Monoclonal Phase 2
19 Antineoplastic Agents, Immunological Phase 2
20
acetic acid Approved 64-19-7 176
21
Proflavine Approved 92-62-6 7099
22
Fenbendazole Vet_approved 43210-67-9 3334
23
Retinol acetate 127-47-9 10245972
24 Lugol's solution
25 Pharmaceutical Solutions
26 Anti-Infective Agents, Local
27 Anti-Infective Agents

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
2 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Active, not recruiting NCT03180034 Phase 4
3 A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity Unknown status NCT01429649 Phase 3
4 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
5 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
6 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
7 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
8 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
9 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Active, not recruiting NCT03998254 Phase 3 V503;Gardasil
10 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
11 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study Completed NCT03053544 Phase 2 Metformin
12 A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
13 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
14 Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer Active, not recruiting NCT01048853 Phase 2
15 Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer Unknown status NCT02941003
16 Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS) Unknown status NCT00898144
17 Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung Unknown status NCT02239432
18 Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil) Unknown status NCT03195218
19 Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings Completed NCT02494310
20 Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study Completed NCT03466710
21 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Recruiting NCT00892866
22 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
23 A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity Recruiting NCT03322826
24 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
25 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
26 A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing Active, not recruiting NCT01946100
27 A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice. Active, not recruiting NCT03438006
28 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Enrolling by invitation NCT02705404
29 A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland Enrolling by invitation NCT01393470
30 Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Sources

Genetic Tests for Adenocarcinoma in Situ

About this section
Sources

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

40
Lung, Cervix, Testes, Lymph Node, Colon, Prostate, Pancreas
Sources

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1295)
# Title Authors PMID Year
1
Histological and prognostic data on surgically resected early-stage lung adenocarcinoma. 61
32551350 2020
2
Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma. 61
32450494 2020
3
Optimization of CT windowing for diagnosing invasiveness of adenocarcinoma presenting as sub-solid nodules. 61
32371183 2020
4
Risk of Recurrence After Treatment for Cervical Intraepithelial Neoplasia 3 and Adenocarcinoma In Situ of the Cervix: Recurrence of CIN 3 and AIS of Cervix. 61
32384365 2020
5
Cervical Stratified Mucin-Producing Intraepithelial Lesion: A Systematic Review of Diagnosis and Management. 61
32332219 2020
6
Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas. 61
32237253 2020
7
Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter. 61
32166405 2020
8
Expert consensus from the Italian Society for Colposcopy and Cervico-Vaginal Pathology (SICPCV) for colposcopy and outpatient surgery of the lower genital tract during the COVID-19 pandemic. 61
32270477 2020
9
Identification of Novel CD74-NRG2α Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers. 61
32036070 2020
10
Do High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital. 61
32569024 2020
11
Changes in the incidence of cervical tumours by disease stage in a cytology-based screening programme. 61
31690178 2020
12
MRI of prostatic urethral mucinous urothelial carcinoma: Expanding the differential diagnosis for T2 hyperintense prostatic masses. 61
32574932 2020
13
Combination of electromagnetic navigation bronchoscopy-guided microwave ablation and thoracoscopic resection: An alternative for treatment of multiple pulmonary nodules. 61
32286013 2020
14
Prognostic role of positron emission tomography and computed tomography parameters in stage I lung adenocarcinoma. 61
32463388 2020
15
Clinical study of serum IGFBP7 in predicting lymphatic metastasis in patients with lung adenocarcinoma. 61
32475626 2020
16
Marginal radiomics features as imaging biomarkers for pathological invasion in lung adenocarcinoma. 61
31965255 2020
17
Atypical glandular lesions of the cervix and risk of cervical cancer. 61
31853943 2020
18
Human papillomavirus genotype contribution to cervical cancer and precancer: Implications for screening and vaccination in Japan. 61
32372453 2020
19
The Evolving Spectrum of Precursor Lesions of Cervical Adenocarcinomas. 61
32482967 2020
20
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. 61
32405745 2020
21
Discriminating between bronchiolar adenoma, adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung with CT. 61
32482582 2020
22
Adenocarcinoma of the lung: from BAC to the future. 61
32430670 2020
23
Analysis of Conization Results in Patients undergoing Hysterectomy for Uterine Adenocarcinoma. 61
32483807 2020
24
Utility of Maximum CT Value in Predicting the Invasiveness of Pure Ground-Glass Nodules. 61
32089477 2020
25
The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China. 61
32429919 2020
26
Is hysterectomy necessary for the treatment of preinvasive stratified mucin producing intraepithelial lesions of the cervix? 61
32448806 2020
27
p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. 61
32238876 2020
28
The evolving spectrum of endocervical adenocarcinoma in situ (AIS). 61
32040619 2020
29
Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type. 61
31932920 2020
30
The newly proposed International Endocervical Adenocarcinoma Criteria and Classification and its relevance to cervical cytology screening assessed in a prospective 2-year study of 118 cases. 61
32289186 2020
31
Feature-shared adaptive-boost deep learning for invasiveness classification of pulmonary subsolid nodules in CT images. 61
32020649 2020
32
CT Characteristics for Predicting Invasiveness in Pulmonary Pure Ground-Glass Nodules. 61
32348187 2020
33
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. 61
32243308 2020
34
Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18. 61
31680146 2020
35
Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma. 61
31483053 2020
36
Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations. 61
32168211 2020
37
Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. 61
31769577 2020
38
ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target. 61
31925985 2020
39
Value of TSCT Features for Differentiating Preinvasive and Minimally Invasive Adenocarcinoma From Invasive Adenocarcinoma Presenting as Subsolid Nodules Smaller Than 3 cm. 61
31201034 2020
40
Simultaneous visualization of pulmonary nodules and intersegmental planes on fluorescent images in pulmonary segmentectomy. 61
32206778 2020
41
Pathologic discrepancies between colposcopy-directed biopsy and loop electrosurgical excision procedure of the uterine cervix in women with cytologic high-grade squamous intraepithelial lesions. 61
31912671 2020
42
SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma. 61
31444787 2020
43
Clinicopathologic Features and Genetic Alterations in Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung: Long-Term Follow-Up Study of 121 Asian Patients. 61
32048092 2020
44
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. 61
30980692 2020
45
Role of PET/CT in Management of Early Lung Adenocarcinoma. 61
31714848 2020
46
Will HPV vaccination prevent cervical cancer? 61
31962050 2020
47
Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. 61
30861114 2020
48
Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study. 61
31578727 2020
49
Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection. 61
32082413 2020
50
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. 61
31692283 2020
Sources

Variations for Adenocarcinoma in Situ

About this section
Sources

Expression for Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.
Sources

Pathways for Adenocarcinoma in Situ

About this section

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.28 PAX8 KRAS EGFR CDKN2A ALK
2
Primary Focal Segmental Glomerulosclerosis FSGS 1
11 WT1 PAX2 CLDN1
3
Bladder cancer 36 1
10.66 KRAS EGFR CDKN2A
Sources

GO Terms for Adenocarcinoma in Situ

About this section

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.1 TOP2A PAX2 EGFR CLDN1 CDX2 ALK
2 MCM complex GO:0042555 8.96 MCM7 MCM2

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.14 PAX8 PAX2 INSM1 GGN EGFR CDX2
2 positive regulation of cell proliferation GO:0008284 10.03 PAX2 KRAS INSM1 EGFR CDX2
3 positive regulation of transcription, DNA-templated GO:0045893 10 WT1 PAX8 PAX2 EGFR CDX2 CDKN2A
4 regulation of protein stability GO:0031647 9.79 KRAS CDKN2A ASPH
5 cellular response to epidermal growth factor stimulus GO:0071364 9.69 PAX2 MCM7 EGFR
6 branching involved in ureteric bud morphogenesis GO:0001658 9.67 WT1 PAX8 PAX2
7 mesonephros development GO:0001823 9.62 PAX8 PAX2
8 double-strand break repair via break-induced replication GO:0000727 9.62 MCM7 MCM2
9 mesenchymal to epithelial transition GO:0060231 9.61 WT1 PAX2
10 metanephric mesenchyme development GO:0072075 9.59 WT1 PAX2
11 cellular response to gonadotropin stimulus GO:0071371 9.58 WT1 PAX8
12 pre-replicative complex assembly involved in nuclear cell cycle DNA replication GO:0006267 9.58 MCM7 MCM2
13 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.57 PAX8 PAX2
14 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.56 PAX8 PAX2
15 pronephros development GO:0048793 9.55 PAX8 PAX2
16 metanephric S-shaped body morphogenesis GO:0072284 9.54 WT1 PAX8
17 metanephric nephron tubule formation GO:0072289 9.48 PAX8 PAX2
18 metanephric distal convoluted tubule development GO:0072221 9.46 PAX8 PAX2
19 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.43 PAX8 PAX2
20 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.4 PAX8 PAX2
21 positive regulation of metanephric DCT cell differentiation GO:2000594 9.37 PAX8 PAX2
22 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.32 PAX8 PAX2
23 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.26 PAX8 PAX2
24 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.16 PAX8 PAX2
25 pronephric field specification GO:0039003 8.96 PAX8 PAX2
26 metanephric epithelium development GO:0072207 8.8 WT1 PAX8 PAX2

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.61 WT1 TOP2A PAX8 PAX2 MCM7 MCM2
2 structural molecule activity GO:0005198 8.92 KRT20 CLDN10 CLDN1 ASPH
Sources

Sources for Adenocarcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....